[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623678":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Sheba Medical Center","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine inhalation group",null,"Treatment-Resistant Depression patient after Ketamine inhalation",[13],"Drug: S (+) Ketamine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","S (+) Ketamine","the patients are treated with S-Ketamine in order to treat there Treatment-Resistant Depression via inhalation",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"revital amiaz, dr","CONTACT","972 035302538","revital.amiaz@sheba.health.gov.il",[27],{"facility":5,"status":10,"city":28,"state":29,"zip":30,"country":29,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Ramat Gan","Israel","52621","IL",{"type":33,"coordinates":34},"Point",[35,36],34.81065,32.08227,{"lat":36,"lon":35},[39,43],{"name":40,"role":23,"phone":41,"phoneExt":10,"email":42},"tzur mayer, dr","972 035303318","tzur.mayer@sheba.health.gov.il",{"name":22,"role":23,"phone":44,"phoneExt":10,"email":25},"972035302538",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100623678","mitochondrial-function-after-ketamine-100623678",false,"NCT07399756","Mitochondrial Function After Ketamine","Assessment of Mitochondrial Parameters in Blood Before and After S-Ketamine Treatment","Inclusion Criteria:\n\nMale or female, 18-65 years of age Diagnosis of Major Depressive Disorder according to the DSM-V Patient has a HAM-D≥23 Treatment resistant -Did not respond to two antidepressants trial Medically stable: No active physical disease: malignancy, cardiac condition, hypertension , stable medications for the past month etc.\n\nExclusion Criteria:\n\nKnown sensitivity to ketamine drug or alcohol abuse Patient taking lithium or corticosteroids Pregnant or breast-feeding has another axis I diagnosis attention deficits disorder a history or current serious neurological, metabolic autoimmune bone marrow, oncologic or additional psychiatric disorders",true,"ALL","18 Years",{"count":58,"type":59},30,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression.\n\nthe Research Questions are\n\n1. Does S-ketamine treatment modulate mitochondrial function in peripheral blood cells, as reflected by mitochondrial content and circulating mitochondrial biomarkers such as GDF15?\n2. Can changes in mitochondrial function serve as biomarkers for predicting or monitoring clinical response to S-ketamine treatment?\n\nSamples will be collected at baseline, 3 hours after the first treatment, and 6 weeks post-exposure, and compared between responders and non-responders",[63],"Major Depressive Disorder",[65],"ketamine, Mitochondrial, Treatment-Resistant Depression","NOT_YET_RECRUITING","2026-02-03",{"date":69,"type":70},"2026-02-10","ACTUAL",{"date":72,"type":59},"2026-02",{"date":74,"type":59},"2028-01",{"name":5,"class":6},1]